Filtered By:
Vaccination: AIDS Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1692 results found since Jan 2013.
Control groups for HIV prevention efficacy trials: what does the future hold?
Curr Opin HIV AIDS. 2023 Sep 12. doi: 10.1097/COH.0000000000000818. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Ending the HIV epidemic will require the development of additional effective immune-mediated and nonimmune-mediated means of HIV prevention. Evaluating novel interventions requires large, controlled trials demonstrating efficacy. Recent advances in the field of HIV prevention necessitate new approaches to efficacy trial design.RECENT FINDINGS: Three classes of efficacy trial designs are possible: standard of prevention-controlled trials, active-controlled trials, and active-controlled trials augmented with e...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Holly Janes Susan Buchbinder Source Type: research
At UNGA, Civil Society Must Mobilize Global Solidarity for Universal Health Coverage
By ,
Founding Executive Director, African Center for Global Health and Social TransformationcbalesSeptember 12, 2023September 12, 2023 12:00 PMAs world leaders prepare for the United Nations General Assembly (UNGA) in New York, it ’s important for those of us in civil society to prepare ourselves ideologically to engage, especially for pushing leaders to make commitments during the UN High-Level Meeting on Universal Health Coverage (UHC) on September 21. The theme for this important gathering is Universal health coverage: expanding our ambition for health and well-being in a post-COVID world.We all have a right to ...
Source: IntraHealth International - September 12, 2023 Category: International Medicine & Public Health Authors: cbales Source Type: news
Assessment of Disease Burden and Immunization Rates for Vaccine-Preventable Diseases in People Living with HIV: The Korea HIV/AIDS Cohort Study
CONCLUSION: The burden of vaccine-preventable diseases was quite high in HIV-infected patients. Nadir CD4 T-cell counts, peak HIV viral loads, and the number of ART regimen change are significant factors related to vaccination. Considering the low vaccination rates for VPDs, there was a discordance between experts' opinions and real clinical practice in the medical field.PMID:37674339 | DOI:10.3947/ic.2023.0045
Source: Herpes - September 7, 2023 Category: Infectious Diseases Authors: Hye Seong Yunsu Choi Kyoung Hwan Ahn Jun Yong Choi Shin-Woo Kim Sang Il Kim Mee-Kyung Kee Bo Youl Choi Boyoung Park Hak Jun Hyun Jin Gu Yoon Ji Yun Noh Hee Jin Cheong Woo Joo Kim Joon Young Song Source Type: research
GMP manufacture of Shigella flexneri 2a Artificial Invaplex (Invaplex < sub > AR < /sub > ) and evaluation in a Phase 1 Open-label, dose escalating study administered intranasally to healthy, adult volunteers
Vaccine. 2023 Sep 2:S0264-410X(23)00995-7. doi: 10.1016/j.vaccine.2023.08.051. Online ahead of print.ABSTRACTShigella species cause severe disease among travelers to, and children living in, endemic countries. Although significant efforts have been made to improve sanitation, increased antibiotic resistance and other factors suggest an effective vaccine is a critical need. Artificial Invaplex (InvaplexAR) is a subunit vaccine approach complexing Shigella LPS with invasion plasmid antigens. In pre-clinical studies, the InvaplexAR vaccine demonstrated increased immunogenicity as compared to the first generation product and w...
Source: Vaccine - September 4, 2023 Category: Allergy & Immunology Authors: Christopher Duplessis Kristen A Clarkson K Ross Turbyfill Ashley N Alcala Ramiro Gutierrez Mark S Riddle Tida Lee Kristopher Paolino Hailey P Weerts Amanda Lynen Edwin V Oaks Chad K Porter Robert Kaminski Source Type: research
Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States
Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.07.077. Online ahead of print.ABSTRACTSocially and medically vulnerable groups (e.g., people 65 years or older, minoritized racial groups, non-telework essential workers, and people with comorbid conditions) experience barriers to COVID-19 prevention and treatment, increased burden of disease, and increased risk of death from COVID-19. Researchers are paying increased attention to social determinants of health (SDH) in explaining inequities in COVID-19-related health outcomes and rates of vaccine uptake. The purpose of the present manuscript is to ident...
Source: Vaccine - August 7, 2023 Category: Allergy & Immunology Authors: Jeanna Campbell Amandeep Kaur Danilo Gamino Ellen Benoit Brianna Amos Liliane Windsor Source Type: research
HIV: the pursuit of an elusive vaccine
Biotechniques. 2023 Aug 4. doi: 10.2144/btn-2023-0059. Online ahead of print.ABSTRACTIn 1984, when it was discovered that the HIV-1 virus caused AIDS, the US Health and Human Services Secretary, Margaret Heckler, declared that a vaccine would be available within 2 years. So why, 40 years on, are we still searching for an HIV vaccine? [Formula: see text].PMID:37539869 | DOI:10.2144/btn-2023-0059
Source: BioTechniques - August 4, 2023 Category: Biotechnology Authors: Annie Coulson Source Type: research
One in five people who contract the COVID-19 virus don ’t get sick. A gene variant may explain why
SARS-CoV-2 kills some of the people it infects and makes many others miserable. But a fortunate few skate through a bout of COVID-19 without suffering symptoms. One key to avoiding illness, according to a new study, is a version of a particular immune system gene that only some people carry. When individuals with this gene variant are exposed to common coronaviruses that cause colds, the research shows, they gain protection against SARS-CoV-2.
“I love this paper,” says immunologist Shane Crotty of the La Jolla Institute for Immunology, who wasn’t connected to the research. The study, he says, provides “the str...
Source: ScienceNOW - July 19, 2023 Category: Science Source Type: news
Can persistent infections with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T- lymphotropic virus (HTLV) be eradicated?
AIDS Res Hum Retroviruses. 2023 Jul 6. doi: 10.1089/AID.2022.0116. Online ahead of print.ABSTRACTPersistent viruses (PV) are hard to be eradicated, even using effective medications, and can persist for a long time in humans, sometimes regardless of treatment. Hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus (HTLV) infections, the most common in our era, is still a challenge despite the increased knowledge about their biology. Most of them are highly pathogenic, some causing acute disease or, more often, leading to chronic persistent infections, and so...
Source: Cell Research - July 6, 2023 Category: Cytology Authors: Sandy Vieira Teixeira Gabriela Silva Prates Luiz Augusto M Fonseca Jorge Casseb Source Type: research
JAMA Internal Medicine —Providing Compelling, Credible, Timely, and Essential Evidence
We live in a time of breathtaking advances in biomedicine. During my lifetime, scientific breakthroughs have made previously fatal or debilitating diseases treatable with revolutionary new drugs or molecularly targeted approaches for AIDS, hepatitis, cancer, and many other conditions across the full spectrum of internal medicine. Medical discovery has also helped set the stage for the highly accelerated development of the COVID-19 vaccine —one of the greatest scientific achievements in history. In stark juxtaposition to these advances, we are facing unprecedented challenges and stressors to our health care systems. Misin...
Source: JAMA Internal Medicine - July 3, 2023 Category: Internal Medicine Source Type: research
